A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets

Active, not recruitingOBSERVATIONAL
Enrollment

125

Participants

Timeline

Start Date

December 27, 2021

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Acute Myeloid Leukemia
Trial Locations (19)

1140

Hanusch Krankenhaus /ID# 247282, Vienna

1160

Klinik Ottakring /ID# 247285, Vienna

1260

Hôpital de Nyon /ID# 240720, Nyon

1847

Hôpital du Chablais, Rennaz /ID# 241895, Rennaz

3010

Inselspital, Universitaetsspital Bern /ID# 239241, Bern

3100

Universitaetsklinikum St. Poelten /ID# 247283, Sankt Pölten

3900

Spitalzentrum Oberwallis /ID# 241897, Brig

4010

Ordensklinikum Linz GmbH Elisabethinen /ID# 247284, Linz

4031

Duplicate_Universitätsspital Basel /ID# 256509, Basel

5001

Kantonsspital Aarau AG /ID# 251598, Aarau

5404

Kantonsspital Baden /ID# 241896, Baden

6000

Luzerner Kantonsspital /ID# 239242, Lucerne

6500

EOC Ospedale Regionale di Bellinzona e Valli /ID# 240663, Bellinzona

8020

Krankenhaus der Barmherzigen Brueder Graz /ID# 254121, Graz

8032

Hirslanden Zürich /ID# 239239, Zurich

8400

KSW Kantonsspital Winterthur /ID# 239852, Winterthur

8700

Landeskrankenhaus Hochsteiermark, Standort Leoben /ID# 254174, Leoben

9007

Kantonsspital St. Gallen /ID# 239233, Sankt Gallen

9020

Klinikum Klagenfurt am Wörthersee /ID# 247304, Klagenfurt

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY